Alexander Spira, MD, PhD, FACP

Panelists discuss treatment selection, resistance challenges, and future directions in managing BRAF-mutated lung cancer.

Panelists discuss the latest trial results supporting dual-pathway inhibition in BRAF-mutated metastatic lung cancer.

Panelists discuss combination targeted approaches for managing BRAF-mutated lung cancer and their impact on disease durability.

Panelists discuss evolving treatment approaches for BRAF-mutated metastatic lung cancer and their clinical impact.

Panelists discuss the biology and clinical implications of BRAF mutations in non–small cell lung cancer (NSCLC).

Panelists discuss individualized treatment selection based on age, comorbidities, and patient preferences in ALK-positive lung cancer.

Panelists discuss novel research directions aimed at overcoming resistance and extending survival in ALK-positive lung cancer.

Panelists discuss mechanisms of acquired resistance to ALK inhibition and how molecular testing guides sequencing strategies.

Panelists discuss how real-world data complement clinical trials in understanding outcomes for ALK-positive lung cancer.

Panelists discuss how mature survival data inform treatment sequencing and maintenance strategies in ALK-positive lung cancer.

Panelists discuss ongoing research and investigational strategies aimed at overcoming resistance in ROS1-driven lung cancer.

Panelists discuss translating clinical trial evidence on ROS1-targeted therapy into real-world patient management.

Panelists discuss the role of ALK rearrangements in lung cancer and the development of successive generations of targeted inhibitors.

Panelists discuss long-term data demonstrating the durability of response and intracranial protection achieved with modern ALK-targeted therapies.

Panelists discuss the molecular and clinical characteristics of ROS1-driven lung cancer and the role of precise molecular testing in guiding targeted therapy.

Panelists discuss first-line treatment strategies for ROS1-positive lung cancer and the factors influencing therapy selection and sequencing.

Alexander I. Spira MD, PhD, FACP, FASCO, details the next steps for amivantamab in patients with EGFR–mutated locally advanced non–small cell lung cancer.

Alexander I. Spira MD, PhD, FACP, FASCO, discusses data of RMC-9805 in previously treated, advanced KRAS G12D–mutated pancreatic ductal adenocarcinoma.

A secondary investigation stemming from the Phase 3 MARIPOSA study, this analysis stratifies outcomes of utilizing amivantamab plus lazertinib compared to osimertinib in the treatment of first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) by biomarkers and disease characteristics indicative of high-risk disease.

Alexander I. Spira, MD, PhD, FACP, discusses the evaluation of the LAG-3 inhibitor fianlimab plus cemiplimabin patients with advanced melanoma who were PD-L1 inhibitor–naïve, as seen in the findings from a phase 1 study.

Alexander I. Spira, MD, PhD, FACP, discusses the FDA approval of adagrasib in patients with KRAS G12C–mutated non–small cell lung cancer.

Closing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.

Expert oncologists consider novel targeted agents in the setting of NSCLC with mutations in HER2, MET exon14, and RET, respectively.

Focusing on ALK-rearranged non–small cell lung cancer, expert panelists review data behind alectinib, brigatinib, and lorlatinib.

Expert perspectives on the management of KRAS G12C–mutant non–small cell lung cancer in the context of novel targeted agents.

Alexander I. Spira, MD, PhD, FACP, discusses additional studies investigating the use of lazertinib and amivantamab in EGFR-mutated non–small cell lung cancer.

Drs Edward S. Kim and Alexander Spira answer viewer questions on ADCs in non-small cell lung cancer.

Alexander I. Spira, MD, PhD, FACP, discusses the exploration of the antibody-drug conjugate tusamitamab ravtansine with pembrolizumab in patients with non–small cell lung cancer.

A discussion on how ADCs affect current standards of care in the non-small cell lung cancer treatment landscape.

Panelists review the data behind treatment options for non–small cell lung cancer expressing EGFR exon 20 insertion mutation.